Skip to main content

Advertisement

SpringerLink
Log in

Saw palmetto and finasteride in the treatment of category-iii prostatitis/chronic pelvic pain syndrome

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is a common entity for which a standardized management has not been established. Patients often have a very little is known about the efficacy of second- and third-line treatments, such as the use of herbal supplements. Many treatments studied in recent literature include antibiotics, á-blockade, anti-inflammatory agents, and cognitive behavioral interventions such as biofeedback and psychotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Collins NM, Stafford RS, O’Leary MP, Barry MJ: How common is prostatitis? A national survey of physician visits. J Urol 1998, 159:1224–1228.

    Article  PubMed  CAS  Google Scholar 

  2. Calhoun EA, McNaughton Collins M, Pontari MA, et al.:The economic impact of chronic prostatitis. Arch Intern Med 2004, 164:1231–1236.

    Article  PubMed  Google Scholar 

  3. Ku JH, Kwak C, Oh SJ, et al.: Influence of pain and urinary symptoms on quality of life in young men with chronic prostatitis-like symptoms. Int J Urol 2004, 11:489–493.

    Article  PubMed  Google Scholar 

  4. Turner JA, Ciol MA, Von Korff M, Berger R: Prognosis of patients with new prostatitis/pelvic pain syndrome episodes. J Urol 2004, 172:538–541.

    Article  PubMed  Google Scholar 

  5. Shortliffe LM, Sellers RG, Schachter J: The characterization of nonbacterial prostatitis: search for an etiology. J Urol 1992, 148:1461–1466.

    PubMed  CAS  Google Scholar 

  6. Hochreiter WW, Duncan JL, Schaeffer AJ: Evaluation of the bacterial flora of the prostate using a 16S rRNA gene-based polymerase chain reaction. J Urol 2000, 163:127–130.

    Article  PubMed  CAS  Google Scholar 

  7. Leskinen MJ, Rantakokko-Jalava K, Manninen R, et al.:Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (CPPS) and localized prostate cancer. Prostate 2003, 55:105–110.

    Article  PubMed  Google Scholar 

  8. Lee JC, Muller CH, Rothman I, et al.: Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from health controls. J Urol 2003, 169:584–588.

    Article  PubMed  Google Scholar 

  9. Kaplan SA, Te AE, Jacobs BZ: Urodynamic evidence of vesical neck obstruction in men with “chronic non-bacterial” prostatitis and the therapeutic role of the endoscopic incision of the bladder neck. J Urol 1995, 152:2063–2065.

    Google Scholar 

  10. Kaplan SA, Santarosa RP, D’Alisera PM, et al.: “Pseudo” dyssynergia (contraction of the external sphincter during voiding) misdiagnosed as “chronic non-bacterial prostatitis” and the role of biofeedback as a therapeutic option. J Urol 1997, 157:897–901.

    Google Scholar 

  11. Kaplan SA, Ikeguchi EF, Santarosa RP, et al.: Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996, 47:836–839.

    Article  PubMed  CAS  Google Scholar 

  12. Nickel JC: Effective office management of chronic prostatitis. Urol Clin North Am 1998, 25:677–684.

    Article  PubMed  CAS  Google Scholar 

  13. Nickel JC, Downey J, Ardern D, et al.: Failure of monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004, 172:551–554.

    Article  PubMed  Google Scholar 

  14. Nickel JC, Narayan P, McKay J, Doyle C: Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized, double-blind trial. J Urol 2004, 171:1594–1597.

    Article  PubMed  CAS  Google Scholar 

  15. Alexander RB, Propert KJ, Schaeffer AJ, et al.: Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004, 141:581–589.

    PubMed  CAS  Google Scholar 

  16. Angell M, Kassirer JP: Alternative medicine-the risks of untested and unregulated remedies. N Engl J Med 1998, 339:839–841.

    Article  PubMed  CAS  Google Scholar 

  17. Consumer Report: Herbal rx for prostate problems: Saw palmetto pills may help—if they contain enough of the right stuff. September 2000.

  18. Feifer AH, Fleshner NE, Klotz L: Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol 2002, 168:150–154.

    Article  PubMed  CAS  Google Scholar 

  19. Gerber GS: Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 2000, 163:1408–1412.

    Article  PubMed  CAS  Google Scholar 

  20. Shoskes DA, Landis JR, Wang Y, et al.: Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004, 172:542–547.

    Article  PubMed  Google Scholar 

  21. Rugendorff EW, Weidner W, Ebeling L, Buck AC: Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostadynia. Br J Urol 1993, 71:433–438.

    Article  PubMed  CAS  Google Scholar 

  22. Di Silverio F, Monti S, Sciarra A, et al.: Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998, 37:77–83.

    Article  Google Scholar 

  23. Span PN, Voller MC, Smals AG, et al.: Selectivity of finasteride as an in vivo inhibitor of 5-alpha reductase isoenzyme activity in the human prostate. J Urol 1999, 161:332–337.

    Article  PubMed  CAS  Google Scholar 

  24. Span PN, Benraad ThJ, Sweep CG, Smals AG: Kinetic analysis of steroid 5-alpha reductase activity at neutral pH in benign prostatic hyperplasic tissue: evidence for type I isozyme in the human prostate. J Steroid Biochem Mol Biol 1996, 57:103–108.

    Article  PubMed  CAS  Google Scholar 

  25. Rhodes L, Primka RL, Berman C, et al.: Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate 1993, 22:43–51.

    Article  PubMed  CAS  Google Scholar 

  26. Strauch G, Perles P, Vergult G, et al.: Comparison of finasteride and Serenoa repens (Permixon) in the inhibitions of 5-alpha reductase in healthy male volunteers. Eur Urol 1994, 26:247–252.

    PubMed  CAS  Google Scholar 

  27. Di Silverio F, D’Eramo G, Lubrano C, et al.: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992, 21:309–314.

    PubMed  Google Scholar 

  28. Carraro JC, Raynaud JP, Koch G, et al.: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized, international study of 1098 patients. Prostate 1996, 29:231–242.

    Article  PubMed  Google Scholar 

  29. Iehle C, Delos S, Guirou O, et al.: Human prostatic steroid 5 alpha reductase isoforms: a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995, 54:273–279.

    Article  PubMed  CAS  Google Scholar 

  30. Sultan C, Terraza A, Devillier C, et al.: Inhibition of androgen metabolism and binding by a liposterolic extraction of “Serenoa repens B”” in human foreskin fibroblasts. J Steroid Biochem 1984, 20:515–519.

    Article  PubMed  CAS  Google Scholar 

  31. Carilla E, Briley M, Fauran F, et al.: Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 1984, 20:521–523.

    Article  PubMed  CAS  Google Scholar 

  32. Ravenna L, Di Silverio F, Russo MA, et al.: Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 1996, 29:219–230.

    Article  PubMed  CAS  Google Scholar 

  33. Paubert-Braquet M, Cousse H, Raynaud JP, et al.: Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998, 33:340–347.

    Article  PubMed  CAS  Google Scholar 

  34. Goldman WH, Sharma AL, Currier SJ, et al.: Saw palmetto berry extract inhibits cell growth and cox-2 expression in prostatic cancer cells. Cell Biol Int 2001, 25:1117–1124.

    Article  CAS  Google Scholar 

  35. Wadsworth TL, Carroll JM, Mallinson RA, et al.: Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 2004, 145:3205–3214.

    Article  PubMed  CAS  Google Scholar 

  36. Vacher P, Prevarskaya N, Skryma R, et al.: The liposterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 1995, 2:357–365.

    Article  PubMed  CAS  Google Scholar 

  37. Goepel M, Hecker U, Krege S, et al.: Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 1999, 38:208–215.

    Article  PubMed  CAS  Google Scholar 

  38. Grasso M, Montesano A, Buonaguidi A, et al.: Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995, 48:97–103.

    PubMed  CAS  Google Scholar 

  39. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD:Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001, 58:960–963.

    Article  PubMed  CAS  Google Scholar 

  40. Marks LS, Partin AW, Epstein JI, et al.: Effects of saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000, 163:1451–1456.

    Article  PubMed  CAS  Google Scholar 

  41. Wilt T, Ishani A, Stark G, et al.: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000, 2:CD001423.

    PubMed  Google Scholar 

  42. Lowe F, Robertson C, Roehrborn A, et al.: Meta-analysis of clinical trials of Permixon. J Urol 1998, 159(suppl):257.

    Google Scholar 

  43. Ernst E: The risk-benefit profile of commonly used herbal therapies: St. John’s Wort, ginseng, Echinacea, saw palmetto, and Kava. Ann Intern Med 2002, 136:42–53.

    PubMed  Google Scholar 

  44. Nickel JC, Downey J, Pontari MA, et al.: A randomized, placebo-controlled, multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 2004, 93:991–995. This is the first placebo-controlled study examining finasteride in men with category IIIA chronic nonbacterial prostatitis.

    Article  PubMed  CAS  Google Scholar 

  45. Kaplan SA, Volpe MA, Te AT: A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004, 171:284–288. This is the first prospective trial evaluating finasteride in men with category IIIA chronic nonbacterial prostatitis.

    Article  PubMed  Google Scholar 

  46. Marks LS, Hess DL, Dorey FJ, et al.: Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001, 57:999–1005. This is the first study that evaluates and compares the tissue effects of saw palmetto and finasteride in humans with biopsy cores.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Weill Medical College of Cornell University, 1300 York Avenue, F918, 10021, New York, NY, USA

    Alexis E. Te MD

Authors
  1. Jennifer Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexis E. Te MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, J., Te, A.E. Saw palmetto and finasteride in the treatment of category-iii prostatitis/chronic pelvic pain syndrome. Curr Urol Rep 6, 290–295 (2005). https://doi.org/10.1007/s11934-005-0026-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-005-0026-1

Keywords

Search

Navigation